Suppr超能文献

小儿梅克尔扫描的预处理:泮托拉唑与雷尼替丁对优化扫描质量的比较

Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality.

作者信息

Önner Hasan, Calderon Tobar Merve Ni̇da, Sarıkaya Mehmet, Özcan Sıkı Fatma, Yılmaz Fari̇se, Körez Muslu Kazim, Kara Gedi̇k Gonca

机构信息

Selçuk University, Medical Faculty, Department of Nuclear Medicine, Konya, Türkiye.

Selçuk University, Medical Faculty, Department of Pediatric Surgery, Konya, Türkiye.

出版信息

Pediatr Radiol. 2025 Jun 14. doi: 10.1007/s00247-025-06284-5.

Abstract

BACKGROUND

The standard method for diagnosing Meckel diverticulum and identifying ectopic gastric mucosa is Tc-pertechnetate imaging. Premedication with H receptor antagonists enhances the scan's sensitivity by reducing the washout of Tc-pertechnetate activity from the intestinal lumen.

OBJECTIVE

After the withdrawal of ranitidine, we compared the efficacy of the proton pump inhibitor pantoprazole as an alternative premedication agent for Tc-pertechnetate Meckel diverticulum imaging.

MATERIALS AND METHODS

This study assessed the scan quality of 141 children (aged 1 month to 204 months (median = 84 months)) who underwent Meckel scintigraphy over 10 years at a single institution. Before its withdrawal in December 2020, ranitidine was utilized for premedication, while pantoprazole was used thereafter. Therefore, patients were divided into two premedication groups: ranitidine (n = 88) and pantoprazole (n = 53). A high-quality scan was defined as having no Tc-pertechnetate activity in the duodenal and other intestinal lumens. The effectiveness of pantoprazole in reducing Tc-pertechnetate release in the duodenum and other intestinal lumens was compared to that of ranitidine. Differences in scan quality between the groups were analyzed using the two-proportion Z-test. In patients with positive scans, the lesion-to-background activity ratio of the Meckel diverticulum was measured and compared between the premedication groups.

RESULTS

Premedication with pantoprazole resulted in 47.2% of scans showing no Tc-pertechnetate release, 37.7% with activity localized either in the duodenum or other intestine, and 15.1% exhibiting activity in both regions. In comparison, ranitidine resulted in 45.5% of scans with no Tc-pertechnetate release, 40.9% with activity localized either in the duodenum or other intestine, and 13.6% showing activity in both regions. P-values were not found to be significant in all comparisons. Twelve scans were positive; all patients had Meckel diverticulum confirmed at surgery. For positive scans, the lesion-to-background activity ratio for the Meckel diverticulum was similar between the ranitidine and pantoprazole groups.

CONCLUSION

This study demonstrates that pantoprazole is statistically non-inferior to ranitidine regarding scan quality and lesion-to-background activity ratios for Meckel diverticulum detection. Pantoprazole offers a reliable alternative for clinical protocols in the absence of ranitidine.

摘要

背景

诊断梅克尔憩室并识别异位胃黏膜的标准方法是锝-高锝酸盐显像。使用H受体拮抗剂进行预处理可通过减少锝-高锝酸盐活性从肠腔的洗脱来提高扫描的敏感性。

目的

在雷尼替丁停用后,我们比较了质子泵抑制剂泮托拉唑作为锝-高锝酸盐梅克尔憩室显像替代预处理药物的疗效。

材料与方法

本研究评估了在单一机构10年间接受梅克尔闪烁扫描的141名儿童(年龄1个月至204个月(中位数=84个月))的扫描质量。在2020年12月停用之前,使用雷尼替丁进行预处理,此后使用泮托拉唑。因此,患者被分为两个预处理组:雷尼替丁组(n = 88)和泮托拉唑组(n = 53)。高质量扫描定义为十二指肠和其他肠腔内无锝-高锝酸盐活性。将泮托拉唑在减少十二指肠和其他肠腔内锝-高锝酸盐释放方面的有效性与雷尼替丁进行比较。使用双比例Z检验分析两组之间扫描质量的差异。在扫描阳性的患者中,测量并比较梅克尔憩室的病变与背景活性比值。

结果

泮托拉唑预处理导致47.2%的扫描显示无锝-高锝酸盐释放,37.7%的活性局限于十二指肠或其他肠道,15.1%的在两个区域均有活性。相比之下,雷尼替丁导致45.5%的扫描无锝-高锝酸盐释放,40.9%的活性局限于十二指肠或其他肠道,13.6%的在两个区域均有活性。所有比较的P值均无统计学意义。12次扫描为阳性;所有患者在手术中均确诊为梅克尔憩室。对于阳性扫描,雷尼替丁组和泮托拉唑组中梅克尔憩室的病变与背景活性比值相似。

结论

本研究表明,在梅克尔憩室检测的扫描质量和病变与背景活性比值方面,泮托拉唑在统计学上不劣于雷尼替丁。在没有雷尼替丁的情况下,泮托拉唑为临床方案提供了可靠的替代选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验